ImmuPharma ( (GB:IMM) ) has provided an update.
ImmuPharma PLC has announced a significant milestone in proving the unique mechanism of action of its P140 autoimmune technology platform. The findings indicate that P140 is non-immunosuppressive, effective, and safe, offering potential as a treatment for systemic lupus erythematosus (SLE). This breakthrough enhances ImmuPharma’s intellectual property portfolio and strengthens its commercial viability, potentially impacting the $360 billion therapy market projected by 2030. The announcement has been described as compelling by company executives, highlighting the potential for P140 to become a central treatment for autoimmune diseases.
More about ImmuPharma
ImmuPharma PLC is a specialty biopharmaceutical company focused on discovering and developing peptide-based therapeutics. The company’s portfolio includes treatments for autoimmune diseases and anti-infectives, with its lead program, P140, targeting Systemic Lupus Erythematosus (SLE) and Chronic Idiopathic Demyelinating Polyneuropathy (CIDP).
YTD Price Performance: 179.58%
Average Trading Volume: 10,278,587
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £16.24M
See more data about IMM stock on TipRanks’ Stock Analysis page.